Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.65 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.48 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.68 |
| ▸ | THRB | P10828 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.65 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL202563 | 1.00 | ALDH1A1 (0.68) | ALDH1A1CYP3A4THRBMEN1MAPT | |
| Hydrochloric Acid SCHEMBL29524042 | 1.00 | ALDH1A1 (0.68) | ALDH1A1CYP3A4THRBMEN1MAPT | |
| SCHEMBL234263 | 0.97 | ALDH1A1 (0.64) | ALDH1A1CYP3A4THRBMEN1MAPT | |
| SCHEMBL29387850 | 0.97 | ALDH1A1 (0.64) | ALDH1A1CYP3A4THRBMEN1MAPT | |
| Hydrochloric Acid SCHEMBL28847767 | 0.93 | ALDH1A1 (0.61) | ALDH1A1CYP3A4THRBMEN1MAPT | |
| SCHEMBL7397514 | 0.89 | ALDH1A1 (0.67) | ALDH1A1CYP3A4THRBMEN1MAPT | |
| SCHEMBL23202512 | 0.85 | ALDH1A1 (0.52) | ALDH1A1CYP3A4THRBMEN1MAPT | |
| SCHEMBL3489685 | 0.84 | NR4A1 (0.74) | ALDH1A1CYP3A4THRBMEN1MAPT | |
| Hydrochloric Acid SCHEMBL30206678 | 0.83 | ALDH1A1 (0.65) | ALDH1A1CYP3A4THRBMEN1MAPT | |
| Hydrochloric Acid SCHEMBL4381317 | 0.81 | ALDH1A1 (1.00) | ALDH1A1CYP3A4THRBMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117310019-A | Method for detecting oxalic acid by using isotope dilution high performance liquid chromatography tandem mass spectrometry | 江苏吉诺思美精准医学科技有限公司 | 2023-12-29 | — | — | CN | claimed |
| US-20230285599-A1 | BIOSENSING COMPOSITION HAVING SENSING GLUCOSE CONTENT, CONTACT LENS AND METHOD OF PREPARATION THEREOF | NATIONAL YANG MING CHIAO TUNG UNIVERSITY (TW) | 2023-09-14 | — | — | US | claimed |
| US-20200131431-A1 | CHEMICAL ADDITIVES AND SURFACTANT COMBINATIONS FOR FAVORABLE WETTABILITY ALTERATION AND IMPROVED HYDROCARBON RECOVERY FACTORS | ALCHEMY SCIENCES INC (US) | 2020-04-30 | — | — | US | claimed |
| CN-117310019-B | Method for detecting oxalic acid by using isotope dilution high performance liquid chromatography tandem mass spectrometry | 江苏吉诺思美精准医学科技有限公司 | 2025-12-26 | — | — | CN | disclosed |
| CN-117310019-A | Method for detecting oxalic acid by using isotope dilution high performance liquid chromatography tandem mass spectrometry | 江苏吉诺思美精准医学科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK | 2023-12-28 | — | — | US | disclosed |
| US-20230285599-A1 | BIOSENSING COMPOSITION HAVING SENSING GLUCOSE CONTENT, CONTACT LENS AND METHOD OF PREPARATION THEREOF | NATIONAL YANG MING CHIAO TUNG UNIVERSITY (TW) | 2023-09-14 | — | — | US | disclosed |
| EP-4217355-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Forkhead Biotherapeutics, inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022066938-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FORKHEAD BIOTHERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-3825312-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Pharmasset LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3492464-B1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-0934924-A1 | NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| US-5754271-A | PHOTOCHROMIC DYES FOR SUNGLASSES AND CONTACT LENSES | ESSILOR INTERNATIONAL (COMPAGNIE GENERAL D'OPTIQUE) (FR) | 1998-05-19 | — | — | US | disclosed |
| EP-0821675-A1 | NOVEL HYDROXAMIC ACID AND AMINO-CARBOXYLATE COMPOUNDS AS METALLOPROTEASE AND TNF INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-02-04 | — | — | EP | disclosed |
| US-5703092-A | TREATING ARTHRITIS, OTHER INFLAMMATORY DISEASES MEDIATED BY MATRIX METALLOPROTEINASE AND/OR TUMOR NECROSIS FACTOR | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| US-5631720-A | POLYMERIC LENS COMPRISING PHOTOCHROMIC COMPOUND COATINGS CHANGING COLOR UPON EXPOSURE TO ULTRAVIOLET RADIATION | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 1997-05-20 | — | — | US | disclosed |
| WO-1996033176-A1 | NOVEL HYDROXAMIC ACID AND AMINO-CARBOXYLATE COMPOUNDS AS METALLOPROTEASE AND TNF INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-24 | — | — | WO | disclosed |
| US-5527911-A | USEFUL IN OPHTHALMIC OPTICS | ESSILOR INTERNATIONAL (FR) | 1996-06-18 | — | — | US | disclosed |
| EP-0700906-A1 | Heterocyclic derivatives of N-phenylamides | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-03-13 | — | — | EP | disclosed |
| US-5496826-A | ANTICONVULSANTS, MELATONERGIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FOXO1, FOXO3, GCKR | GAA 572/4885CA2 4280/4885SCN2A 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.